10-K · March 5, 2026
Bioventus closed FY2025 with stable top-line (FY2025 revenue ~$569.0M) while delivering meaningfully higher profitability and cash generation versus FY2024. Management highlights regulatory progress in PNS (510(k)…
Earnings analysis · 10-Q
BVS earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
Bioventus reported Q1 2026 revenue of $132.1 million and EPS of $0.04, exceeding estimates. Both U.S. and International segments showed growth, with total net sales increasing 6.6% year-over-year. Management highlighted…
Read full summary
Bioventus reported Q1 2026 revenue of $132.1 million and EPS of $0.04, exceeding estimates. Both U.S. and International segments showed growth, with total net sales increasing 6.6% year-over-year. Management highlighted strong cash flow and reduced debt, keying on an optimistic outlook for the year.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.04
What stood out
-
Revenue Beat Estimates
Q1 2026 revenue of $132.1 million exceeded estimates by $2.4 million, a 6.6% increase from $123.9 million in Q1 2025.
-
Improved EPS
Earnings per share reported at $0.04, recovering from a loss of $0.04 in the prior year.
-
Strong Cash Flow
Net cash from operating activities increased by $28.3 million year-over-year, totaling $8.9 million.
-
Debt Reduction
Discretionary prepayments of $22.0 million on long-term debt were made, helping to reduce interest expenses.
-
Segment Growth
International net sales grew by 17.1% year-over-year, totaling $15.6 million, driven by Pain Treatments and Surgical Solutions.
-
Increased Adjusted EBITDA
Adjusted EBITDA grew to $23.9 million, up from $19.2 million, marking a 24% increase year-over-year.
What to watch
-
Regulatory Investigations
Shareholder litigation continues against the company, raising potential legal risks.
-
High Dependence on Receivables
Management hinted at potential issues if cash flow trends reverse due to elevated receivables.
-
Interest Rate Vulnerability
Rising interest rates could impact future financing costs, affecting profitability.
Management's outlook
Raised guidance for Non-GAAP EPS and cash from operations.
Earlier filings 4
10-K · March 11, 2025
Bioventus positions itself as a specialist musculoskeletal medical device company organized across Pain Treatments, Surgical Solutions and Restorative Therapies, and emphasizes expansion of its neXus/BoneScalpel…
10-Q · August 6, 2024
Bioventus reported Q2 net sales of $151,217 (vs $137,069 a year ago), with gross profit of $103,639 (≈68.6% margin). Despite top-line growth and positive operating cash flow year-to-date, the quarter included a $31,870…
10-Q · November 21, 2022
Bioventus reported Q3 net sales of $128,662,000, up from $108,890,000 a year ago (+$19.8M, +18.2%), but posted a large operating loss of $(200,855,000) driven principally by a $189,197,000 goodwill impairment. Gross…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.